This company has been acquired
Ambrx Biopharma Management
Management criteria checks 1/4
Ambrx Biopharma's CEO is Dan O'Connor, appointed in Nov 2022, has a tenure of 1.33 years. total yearly compensation is $1.03M, comprised of 6.7% salary and 93.3% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth $1.35M. The average tenure of the management team and the board of directors is 1.1 years and 1.5 years respectively.
Key information
Dan O'Connor
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 6.7% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.08% |
| Management average tenure | 1.1yrs |
| Board average tenure | 1.5yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$67m |
| Jun 30 2023 | n/a | n/a | -US$60m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$1m | US$69k | -US$78m |
Compensation vs Market: Dan's total compensation ($USD1.03M) is below average for companies of similar size in the US market ($USD4.96M).
Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.
CEO
Dan O'Connor (58 yo)
1.3yrs
Tenure
US$1,034,168
Compensation
Mr. Daniel J. O'Connor, J.D., also known as Dan, served as an Independent Director of ZyVersa Therapeutics, Inc. since December 13, 2022 until May 2023. He serves as President, CEO and Director of Ambrx Bi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.03m | 0.076% $ 1.3m | |
| Chief Financial Officer | 2.8yrs | US$1.73m | 0.036% $ 641.7k | |
| Chief Operating Officer | less than a year | no data | 0% $ 0 | |
| Chief Technology Officer | 2.2yrs | no data | no data | |
| Chief Scientific Officer & GM of China | 1.4yrs | no data | no data | |
| Senior VP | less than a year | no data | no data | |
| Vice President of Human Capital | 1yr | no data | no data | |
| Chief Clinical Officer | 1.1yrs | no data | no data | |
| Chief Regulatory Officer | less than a year | no data | no data |
1.1yrs
Average Tenure
55yo
Average Age
Experienced Management: AMAM's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.03m | 0.076% $ 1.3m | |
| Independent Director | 2.1yrs | US$268.55k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Chairman of the Board | less than a year | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.7yrs | US$555.41k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.8yrs | US$156.12k | 0% $ 0 |
1.5yrs
Average Tenure
59yo
Average Age
Experienced Board: AMAM's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/06 21:17 |
| End of Day Share Price | 2024/03/06 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ambrx Biopharma Inc. is covered by 7 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |
| Louise Chen | Cantor Fitzgerald & Co. |